Board to consider Final Dividend
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 26, 2017, inter alia:1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2017; and2. To consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2017. Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited Scheduled To Be Held On Friday, 26Th May, 2017.
Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 26th May, 2017, inter alia, (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2017;... Change in Directorate
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish inform you that Mr. Mangaldas Chhaganlal Shah has resigned from the position of Independent Director of the Company with effect from 17th May, 2017, due to personal reasons. The Company appreciates the valuable services rendered by him during his tenure as an Independent Director of the Company. Kindly take note of the same. Notice of Postal Ballot
This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 the Company is in the process of conducting postal ballot (including voting by electronic means) for seeking approval of members of the Company for alteration of the Articles of Association of the Company. In terms of Regulation... Statement Of Investor Grievances For The Quarter Ended 31St March, 2017
In terms of Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Statement of Investor Grievances for the quarter ended 31st March, 2017. Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2017
In terms of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Certificate received from Practising Company Secretary for the half year ended 31st March, 2017. Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period 1St October, 2016 To 31St March, 2017.
As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both, physical and electronic share transfer facility for Alkem Laboratories Limited (hereinafter referred to as 'the Company') are maintained during the period from 1st October, 2016 to 31st March, 2017 (both days inclusive) by the Company's Registrar and Share Transfer Agent,...
FDA closes inspection of Alkem's Ankaleshwar plant
The US FDA, which had inspected Alkem's Ankaleshwar API Facility in December, had earlier issued a form 483 to the company with its observations. Alkem says that the FDA has now closed the inspection, following the corrective and preventive action plan (CAPA) that the company submitted to the regulator. The US FDA, Alkem says, reviewed the CAPA and has found the steps outlined acceptable. Alkem Laboratories saw strong Q3 results, and analysts in their reports had noted that Alkem EBITDA was higher than estimated, with both domestic and US formulations performing well. Axis Direct had issued a BUY call on the stock in February, saying that Alkem has been outpacing domestic market growth in Pharma. The stock has been moderately bullish - share price of Alkem hit a new 52 week high in the past week. Photo source: AlkemLabs Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samprada & Nanhamati Singh Family Trust (Trustee, Samprada & Nanhamati Singh Family Trust ) Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samprada Singh, Balmiki Prasad Singh, Manju Singh, Sarandh Singh, Srinivas Singh, Satish Kumar Singh, Premlalat Singh,Sarvesh Singh, Annapurna Singh, Sandeep Singh & Inderjit Arora